Researchers from CSIRO, Australia's national science agency, have unveiled a new approach to analysing the genetic codes - or the blueprint - of the SARS-CoV-2 virus that causes COVID-19.
Convalescent plasma therapy for COVID-19 patients — an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection — is the focus of a new two-part research initiative at Penn Medicine. Researchers will first collect plasma from people who have recovered from their infection under a donor research protocol. The second part involves conducting clinical trials to test the safety and efficacy of giving that plasma to moderately and severely ill hospitalized patients.
Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, to support the development of a vaccine, TNX-1800, against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform.
Physicians and scientists at UC San Diego Health have launched a pair of serological tests that will look for novel coronavirus antibodies—evidence in persons tested that they have previously been infected by the viral cause of COVID-19, even if they never experienced tell-tale symptoms.
The lab is responding to the coronavirus crisis by imaging disease-related biomolecules, developing standards for reliable coronavirus testing and enabling other essential research.
Recovery. Reentry. Reopen. Return. A new normal. Faculty experts at DePaul University are available for news media interviews about what comes next — after the COVID-19 pandemic. Does the world return to normal or will there be fundamental changes to how we live our lives, work, and travel; and how we are governed?
Supriya Munshaw, a senior lecturer at Johns Hopkins Carey Business School, offers insights on the likely time frame for a coronavirus vaccine, the steps involved in developing one, the most promising candidates currently in the labs of biotech companies, and why, years after the MERS and SARS outbreaks, a coronavirus vaccine still has not been produced.
In the race to identify solutions to the COVID-19 pandemic, researchers at the Department of Energy’s Oak Ridge National Laboratory are joining the fight by applying expertise in computational science, advanced manufacturing, data science and neutron science.
Berkeley Lab's Advanced Light Source X-ray facility has been recalled to action to support research related to COVID-19, the coronavirus disease that has already infected about 2 million people around the world.
At Oak Ridge National Laboratory, it’s all-hands-on-deck for the world-leading experts in neutron scattering as they enter the fight against COVID-19. Researchers at the lab’s Spallation Neutron Source and High Flux Isotope Reactor have a plan of attack to unleash a full barrage of neutron capabilities in an ambitious set of experiments that will provide critical pieces of information about the virus’s biological structure and how it behaves.
Researchers and clinicians are scrambling to find ways to combat COVID-19, including new therapeutics and eventually a vaccine. In a commentary published in the journal Diabetes Research and Clinical Practice, Miller School of Medicine professor and endocrinologist Gianluca Iacobellis, M.D., Ph.D., suggests the DPP4 enzyme presents an interesting target for further research, and DPP4 inhibitors could help some COVID-19 patients.
Harvinder Gill, the Whitacre Endowed Chair of Science and Engineering and an associate professor of chemical engineering in Texas Tech University’s Edward E. Whitacre Jr. College of Engineering, explains what microneedles are, what makes them ideal for vaccine delivery and their potential in other medical areas.
As scientists and doctors around the country step up to meet the COVID-19 pandemic threat, a physician and a laboratory scientist are sending aid to the heart of the effort to develop a vaccine through a generous donation to Saint Louis University’s Center for Vaccine Development.
In an article published recently in the journal Vaccine, two researchers in the Texas Tech University Department of Psychological Sciences suggest some people find vaccines risky because they overestimate the likelihood of negative events, particularly those that are rare.
A decade ago, when the National Institutes of Health needed to place a high-security biocontainment laboratory in Kentucky, capable of safely studying dangerous and emerging infectious diseases, they turned to the University of Louisville.
No vaccines exist that protect people against infections by coronaviruses, including SARS-CoV-2, which causes COVID-19, or the ones that cause SARS and MERS. As COVID-19 continues to wreak havoc, many labs around the world have developed a laser-like focus on understanding the virus and finding the best strategy for stopping it.
The fastest recipe for worldwide access to a coronavirus vaccine may be to build upon on an existing vaccine with an already established manufacturing and supply chain.
The National Institutes of Health has awarded Tulane National Primate Research Center a contract of up to $10.3 million to evaluate vaccines and treatments to combat coronavirus disease 2019.
Announcement from the Harrington Discovery Institute at University Hospitals of a new initiative that galvanizes its transatlantic network of academic institutions, foundations, and philanthropic partners to accelerate promising, near-term therapies to treat COVID-19 and its complications and battle future pandemic threats. In advancing its portfolio of 120 drugs-in-the-making at 54 leading academic centers in North America and the U.K., HDI has developed a proven model that has enabled scientists in academia to accelerate their breakthrough drug discoveries toward trials in patients.
Researchers and faculty from multiple disciplines across the University of Kentucky are coming together as part of the global effort to treat, understand and eradicate COVID-19. A new workgroup within UK’s College of Medicine is bringing together experts from across the campus to focus on advising COVID-19 patient care and clinical trials based on emerging research and potential treatment options.
Summaries of recent Fred Hutch research findings with links for additional background and media contacts.
An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu.
Indiana Researcher looking at rotavirus to develop a vaccine that will protect children against COVID-19.
A potential COVID-19 vaccine, delivered by microscopic needles, produces antibodies specific to the virus when tested in mice. This is the first peer-reviewed paper describing a COVID-19 vaccine candidate. The next step is a human clinical trial.
University of Kentucky virologist Rebecca Dutch answers key questions related to the novel coronavirus. Dutch discusses the virus’ origin, transmission rates, mutation, testing, the difference between COVID-19 and SARS/MERS, and more.
As scientists forge ahead to piece together a comprehensive profile of the new coronavirus fueling a historic pandemic, they are focusing their efforts on six areas: epidemiology, diagnostics, pathogenesis, clinical disease management, treatment and vaccines.
Activity from phony Twitter accounts established by the Russian Internet Research Agency between 2015 and 2017 may have contributed to politicizing Americans’ position on the nature and efficacy of vaccines, a health care topic which has not historically fallen along party lines, according to new research published in the American Journal of Public Health.
Using a research assay called VirScan, scientists plan to study how antibodies from people who have had COVID-19 attack the virus that causes it.
Vaccine expert working on developing covid-19 vaccine, sees major differences between Covid-19 and SARS
A team of scientists, including Case Western Reserve University chemistry Professor Blanton Tolbert and his research lab, are conducting the underlying research to develop an antiviral to slow the spread of novel coronavirus that causes COVID-19.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease
Researchers at Harvard Medical School and at Brigham and Women’s Hospital are adapting an antibody-detection tool to study the aftermath of infections by the novel coronavirus that is causing the current global pandemic.
Penn Medicine has established a new center to help expand and accelerate research related to the novel coronavirus, SARS-CoV-2, that causes the respiratory illness known as COVID-19.The center aims to advance research to support the development of potential vaccines, diagnostic tools, and therapies
SARS-CoV-2, the virus that causes COVID-19, continues to spread, leading to more than 20,000 deaths worldwide in less than four months. Efforts are progressing to develop a COVID-19 vaccine, but it's still likely 12 to 18 months away.
Lawrence Livermore National Laboratory scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover candidates for new antibodies and pharmaceutical drugs to combat the disease.
Up until recently, COVID-19 (coronavirus disease 2019) may have been a relatively new phenomena to the general public, but Wichita State University medical chemist Bill Groutas, two virologists from Kansas State University, and a physician/virologist from the University of Iowa have been working on a cure for coronaviruses for more than three years.
Initial studies with COVID-19 coronavirus aim to replicate prior successful preclinical experiments of LEAPS against H1N1pandemic flu in mice conducted with National Institutes for Allergies and Infectious Diseases (NIAID)
Drugs that are already approved by the U.S. Food and Drug Administration (FDA) could hold promise in fighting the new infection known as coronavirus disease 2019 (COVID-19), according to computer modeling studies performed by UTSW scientists.
The Association for Psychological Science has made previously published journal research pertaining to epidemics and related health issues publicly available.
Newswise Live Expert Panel discussion of unique angles to the COVID-19 outbreak of interest to the public and the media, including public health, testing, business and financial markets, 2020 elections, and more.
Though COVID-19 so far appears to be largely sparing children, researchers are cautioning that it is critical to understand how the virus affects kids to model the pandemic accurately, limit the disease’s spread and ensure the youngest patients get the care they need.
The Department of Energy has a vital role to play in the national response to COVID-19. Researchers have already used tools at national laboratories to make major inroads to analyzing the virus and its spread.
At a presentation at UAB, NIH director Francis Collins outlined the top 10 area of excitement and promise in science.
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right